U.S. Markets closed
  • S&P Futures

    3,627.25
    -9.25 (-0.25%)
     
  • Dow Futures

    29,753.00
    -121.00 (-0.41%)
     
  • Nasdaq Futures

    12,270.00
    +12.50 (+0.10%)
     
  • Russell 2000 Futures

    1,844.10
    -8.90 (-0.48%)
     
  • Crude Oil

    45.05
    -0.48 (-1.05%)
     
  • Gold

    1,784.20
    -3.90 (-0.22%)
     
  • Silver

    22.44
    -0.20 (-0.88%)
     
  • EUR/USD

    1.1975
    +0.0004 (+0.0359%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • Vix

    20.84
    -0.41 (-1.93%)
     
  • GBP/USD

    1.3339
    +0.0025 (+0.1841%)
     
  • USD/JPY

    103.8840
    -0.2010 (-0.1931%)
     
  • BTC-USD

    18,420.50
    +69.05 (+0.38%)
     
  • CMC Crypto 200

    363.72
    +26.22 (+7.77%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,651.44
    +6.73 (+0.03%)
     

Recap: Seres Therapeutics Q2 Earnings

Benzinga Insights
·1 min read

Shares of Seres Therapeutics (NASDAQ:MCRB) fell 6.4% after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 16.67% over the past year to ($0.28), which missed the estimate of ($0.26).

Revenue of $6,045,000 declined by 51.76% year over year, which missed the estimate of $9,540,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

View more earnings on MCRB

Seres Therapeutics hasn't issued any revenue guidance for the time being.

Technicals

52-week high: $6.75

Company's 52-week low was at $2.15

Price action over last quarter: down 8.70%

Company Description

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.